McKesson Corp (MCK)

MCK

About

McKesson Corporation (McKesson) delivers pharmaceuticals, medical supplies and health care information technologies. The Company operates in two segments. The McKesson Distribution Solutions segment distributes drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America. The... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.79
Market Cap (Mil.):	$26,583.75
Shares Outstanding (Mil.):	226.61
Dividend:	0.20
Yield (%):	0.68

Financials

	MCK	Industry	Sector
P/E (TTM):	20.99	34.04	34.30
EPS (TTM):	5.59	--	--
ROI:	10.77	19.04	18.43
ROE:	19.25	19.78	19.30

Latest News about MCK

CORRECTED-BRIEF-McKesson Q4 results

(In May 7 story, corrects seventh bullet point to show analysts' estimate for 2014 profit was $8.06 per share, not $7.21)

08 May 2013

McKesson forecasts fiscal 2014 profit above market estimates

May 7 - Drug wholesaler McKesson Corp reported a smaller-than-expected fourth-quarter profit, but forecast strong 2014 adjusted earnings as it expects its technology solutions business and the acquisition of smaller peer PSS World Medical to significantly contribute to growth.

07 May 2013

Fitch Rates McKesson's Proposed Senior Unsecured Notes 'A-'

(The following statement was released by the rating agency) CHICAGO, March 05 (Fitch) Fitch Ratings has assigned an 'A-' rating to McKesson Corporation's (McKesson) planned issuance of $900 million of new senior unsecured notes. Proceeds will be used to repay amounts drawn on the company's bridge facility to finance the purchase of PSS World Medical Inc. (PSS World) in February 2013. A full list of McKesson's ratings is provided at the end of this release. The Rating Outlook is Stable. KEY

05 Mar 2013

McKesson posts lower-than-expected quarterly profit

- U.S. drug wholesaler McKesson Corp reported a lower-than-expected quarterly net profit on Thursday, citing a $40 million charge for a Canadian legal dispute and deferred international revenue.

31 Jan 2013

BRIEF-McKesson shares down 8.8 pct after the bell following results

NEW YORK, Jan 31 - McKesson Corp : * Shares were down 8.8 percent after the bell after the release of its results.

31 Jan 2013

TEXT-Fitch affirms McKesson's ratings at 'A-'

Dec 5 - Fitch Ratings has affirmed the long-term ratings, including the Issuer Default Rating (IDR), of McKesson Corporation (MCK) at 'A-'. A full list of rating actions is provided at the end of this release. The ratings apply to approximately $4.5 billion of debt outstanding as of the date of this release. The Rating Outlook is Stable. KEY RATING CONSIDERATIONS -- Steady pharmaceutical demand and the oligopolistic market position support a stable operating profile. -- The branded patent cl

05 Dec 2012

TEXT-S&P rates McKesson Corp. proposed notes 'A-'

Nov 29 - Standard & Poor's Ratings Services said today that it assigned U.S.-based medical products and pharmaceutical distributor McKesson Corp.'s proposed senior unsecured notes offering its 'A-' issue-level rating. The notes will be issued in two tranches, and terms of the proposed notes, including maturities, amounts, and rates, will be determined by market conditions. The notes will rank equally with the company's existing and future unsecured and unsubordinated indebtedness. McKesson

29 Nov 2012

TEXT - Fitch rates McKesson Corp snr unsecured notes 'A-'

Nov 29 - Fitch Ratings has assigned an 'A-' rating to McKesson Corporation's (McKesson) planned issuance of $900 million of new senior unsecured notes. Proceeds are intended to refinance $400 million of notes that were repaid in February 2012 and to prefund $500 million of notes due in March 2013. A full list of McKesson's ratings is provided at the end of this release. The Rating Outlook is Stable. KEY RATING CONSIDERATIONS -- Continued stable operating profile with low but steady margins,